Table 1.
Population baseline characteristics and sub-analysis according to mean platelet volume
| |
Overall |
MPV ≤ 9.4 fL |
MPV > 9.4 fL |
P |
|---|---|---|---|---|
| (n = 427) | (n = 245) | (n = 182) | ||
| Demographics | ||||
| Age |
68.2 ± 10.7 |
67.5 ± 11.5 |
69.0 ± 9.3 |
0.133 |
| ♀ |
32.1% (137) |
31.4% (77) |
33.0% (60) |
0.736 |
| Body Mass Index (Kg/m2) |
28.7 ± 5.2 |
29.2 ± 4.4 |
28.1 ± 6.0 |
0.014 |
| Clinical data | ||||
| Congestive heart failure |
49.4% (211) |
45.7% (112) |
54.4% (99) |
0.076 |
| Hypertension |
83.4% (356) |
83.3% (204) |
83.5% (152) |
0.945 |
| Diabetes mellitus |
24.6% (105) |
24.1% (59) |
25.3% (46) |
0.777 |
| Stroke or TIA |
15.2% (65) |
12.2% (30) |
19.2% (35) |
0.047 |
| Vascular diseasea |
49.6% (212) |
46.5% (114) |
53.8% (98) |
0.135 |
| AF episode duration >1 week |
77.8% (332) |
74.7% (183) |
81.9% (149) |
0.078 |
| CHADS2 score |
2.1 ± 1.2 |
2.0 ± 1.2 |
2.3 ± 1.3 |
0.034 |
| CHA2DS2-VASc score |
3.7 ± 1.7 |
3.5 ± 1.8 |
3.9 ± 1.7 |
0.081 |
| Medication | ||||
| Oral anticoagulants |
34.4% (147) |
33.9% (83) |
35.2% (64) |
0.782 |
| Enoxaparin |
31.1% (133) |
32.2% (79) |
29.7% (54) |
0.570 |
| Antiplatelet agents |
48.9% (209) |
48.6% (119) |
49.5% (90) |
0.857 |
| ACE-i or ARB-II |
69.6% (297) |
65.7% (161) |
74.7% (136) |
0.045 |
| Statin |
41.2% (176) |
39.6% (97) |
43.4% (79) |
0.428 |
| Laboratory assessment | ||||
| Haemoglobin (g/dL) |
13.8 ± 1.9 |
13.9 ± 1.9 |
13.6 ± 1.8 |
0.089 |
| Leukocytes (103/uL) |
7.5 ± 3.1 |
7.4 ± 2.8 |
7.8 ± 3.6 |
0.247 |
| Platelets (103/uL) |
222.6 ± 86.2 |
240.6 ± 95.2 |
198.4 ± 65.1 |
<0.001 |
| Plaquetocrit (%) |
20.5 ± 7.2 |
20.8 ± 7.9 |
20.2 ± 6.2 |
0.774 |
| MPV (fL) |
9.3 ± 1.1 |
|
|
|
| PDW (%) |
16.2 ± 1.3 |
16.1 ± 1.4 |
16.3 ± 1.2 |
0.151 |
| INR |
1.4 ± 0.7 |
1.4 ± 0.7 |
1.4 ± 0.7 |
0.583 |
| INR ≥ 2.0 |
17.1% (73) |
16.3% (40) |
18.1% (33) |
0.624 |
| aPTT time (s) |
34.1 ± 7.7 |
33.0 ± 6.0 |
35.6 ± 9.5 |
0.078 |
| Creatinine (umol/L) |
111.7 ± 93.9 |
111.4 ± 107.8 |
112.1 ± 71.4 |
0.329 |
| Estimated GFR – MDRD |
71.1 ± 27.5 |
72.4 ± 26.8 |
69.3 ± 28.5 |
0.262 |
| CRP (mg/L) |
1.7 ± 3.5 |
1.5 ± 2.7 |
2.1 ± 4.3 |
0.213 |
| Troponin I (ng/mL) |
0.03 ± 0.07 |
0.03 ± 0.04 |
0.04 ± 0.10 |
0.032 |
| Transthoracic echocardiogram data | ||||
| iLAV (ml/m2) |
60.4 ± 24.5 |
56.7 ± 21.9 |
64.7 ± 26.6 |
0.006 |
| iLVdd (mm/m2) |
29.6 ± 5.6 |
28.8 ± 5.5 |
30.5 ± 5.6 |
0.010 |
| LVEF < 55% | 24.8% (106) | 24.5% (60) | 25.3% (46) | 0.853 |
Legend: MPV Mean platelet volume, TIA Transient ischemic attack, AF Atrial fibrillation, ACE-i Angiotensin converting enzyme inhibitor, ARB-II Angiotensin II receptor blocker, PDW Platelet distribution width, INR International normalized ratio, CRP, C reactive protein, GFR Glomerular filtration rate, MDRD Modified diet in renal disease formula, LV Left ventricle, LAAT Left atrial appendage thrombi, DSEC Dense spontaneous echo contrast, LFV flow velocities Lowin the left atrial appendage, LA ABN Left atrial abnormality, aPTT Activated partial thromboplastin time, iLAV Indexed left atrial volume, iLVdd Indexed left ventricle diastolic diameter, LVEF Left ventricle ejection fraction.
a vascular disease is defined as having at least one of the following: myocardial infarction, peripheral artery disease and complex aortic plaque.